Anti-human papillomavirus 16 E6 T cell receptors

A method of treating or preventing cancer in a mammal, comprising administering a population of cells to the mammal in an amount effective to treat or prevent the cancer in the mammal, wherein:

• the population of cells comprises at least one host cell expressing a T-cell receptor (TCR) having antigenic specificity for HPV 16 E6 and comprising the alpha chain CDR1 amino acid sequence of SEQ ID NO:
• 3, the alpha chain CDR2 amino acid sequence of SEQ ID NO:
• 4, the alpha chain CDR3 amino acid sequence of SEQ ID NO:
• 5, the beta chain CDR1 amino acid sequence of SEQ ID NO:
• 6, the beta chain CDR2 amino acid sequence of SEQ ID NO:
• 7, and the beta chain CDR3 amino acid sequence of SEQ ID NO:
• 8;
• and
• the cancer is acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the oral cavity, cancer of the vagina, cancer of the vulva, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, esophageal cancer, uterine cervical cancer, gastrointestinal carcinoid tumor, glioma, Hodgkin lymphoma, hypopharynx cancer, kidney cancer, larynx cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharynx cancer, non-Hodgkin lymphoma, cancer of the oropharynx, ovarian cancer, cancer of the penis, pancreatic cancer, peritoneum, omentum, and mesentery cancer, pharynx cancer, prostate cancer, rectal cancer, renal cancer, skin cancer, small intestine cancer, soft tissue cancer, stomach cancer, testicular cancer, thyroid cancer, cancer of the uterus, ureter cancer, and urinary bladder cancer.